HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Senior Reporter

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues

Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.

Legal Issues Intellectual Property

Viatris Looks To Call It A Day In US Januvia, Janumet Patent Saga

Viatris and Merck have disclosed plans to settle litigation currently pending before the US Court of Appeals for the Federal Circuit over the ANDA sponsor’s generic versions of its sitagliptin-containing medicines, Januvia (sitagliptin) and Janumet (sitagliptin/metformin).

Intellectual Property Deals

FTC Fights Sage’s Corner In US Apokyn Antitrust Suit

The US Federal Trade Commission has tackled arguments from Supernus Pharmaceuticals, as the firm looks to dismiss an antitrust case alleging that it unlawfully blocked generic competition to its Apokyn (apomorphine) injectable treatment for advanced Parkinson’s Disease.

Legal Issues Generic Drugs

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.

Biosimilars Biologics

Waverley Weighs Its Options With High Costs, Thin Margins

Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

Generic Drugs Strategy

Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled

In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.

Generic Drugs Strategy
See All
UsernamePublicRestriction

Register